Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

IL-31: A new key player in dermatology and beyond
Işın Sinem Bağci, Thomas Ruzicka
Journal of Allergy and Clinical Immunology (2018) Vol. 141, Iss. 3, pp. 858-866
Open Access | Times Cited: 122

Showing 1-25 of 122 citing articles:

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 2, pp. 141-150
Open Access | Times Cited: 257
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Sonja Ständer, Gil Yosipovitch, Franz J. Legat, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 8, pp. 706-716
Open Access | Times Cited: 230
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
Jonathan I. Silverberg, Andreas Pinter, Grażyna Pulka, et al.
Journal of Allergy and Clinical Immunology (2019) Vol. 145, Iss. 1, pp. 173-182
Open Access | Times Cited: 216
Interleukin‐31: The “itchy” cytokine in inflammation and therapy
Angeliki Datsi, Martin Steinhoff, Fareed Ahmad, et al.
Allergy (2021) Vol. 76, Iss. 10, pp. 2982-2997
Open Access | Times Cited: 140
Neuroimmune communication regulating pruritus in atopic dermatitis
Martin Steinhoff, Fareed Ahmad, Atul Kumar Pandey, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 6, pp. 1875-1898
Open Access | Times Cited: 85
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study
Howard Sofen, Robert Bissonnette, Gil Yosipovitch, et al.
EClinicalMedicine (2023) Vol. 57, pp. 101826-101826
Open Access | Times Cited: 45
Pathophysiologic mechanisms of itch in bullous pemphigoid
Takashi Hashimoto, Christina Kursewicz, Rachel Fayne, et al.
Journal of the American Academy of Dermatology (2019) Vol. 83, Iss. 1, pp. 53-62
Closed Access | Times Cited: 94
Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
Hidemi Nakagawa, Osamu Nemoto, Atsuyuki Igarashi, et al.
The Journal of Dermatology (2019) Vol. 47, Iss. 2, pp. 114-120
Open Access | Times Cited: 82
Interleukin-31 as a Clinical Target for Pruritus Treatment
Kenji Kabashima, Hiroyuki Irie
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 80
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies*
Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 4, pp. 642-651
Open Access | Times Cited: 74
Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization
Micah Belzberg, Martin P. Alphonse, Isabelle Brown, et al.
Journal of Investigative Dermatology (2021) Vol. 141, Iss. 9, pp. 2208-2218.e14
Open Access | Times Cited: 72
Th2 Modulation of Transient Receptor Potential Channels: An Unmet Therapeutic Intervention for Atopic Dermatitis
Jianghui Meng, Yanqing Li, Michael J. M. Fischer, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 71
Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis
Ai Kuzumi, Ayumi Yoshizaki, Kazuki Matsuda, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 59
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis
Celina Dubin, Ester Del Duca, Emma Guttman‐Yassky
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 8, pp. 835-852
Closed Access | Times Cited: 59
Oncostatin M can sensitize sensory neurons in inflammatory pruritus
Pang‐Yen Tseng, Mark A. Hoon
Science Translational Medicine (2021) Vol. 13, Iss. 619
Open Access | Times Cited: 58
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
El‐Bdaoui Haddad, Sonya Cyr, Kazuhiko Arima, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 7, pp. 1501-1533
Open Access | Times Cited: 45
IL-31–generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin
Takashi Hashimoto, Hiroo Yokozeki, Hajime Karasuyama, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 3, pp. 737-746.e6
Closed Access | Times Cited: 42
Mechanistic insights into the antipruritic effects of lebrikizumab, an anti–IL-13 mAb
Yannick Miron, Paul E. Miller, Chloe Hughes, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 150, Iss. 3, pp. 690-700
Open Access | Times Cited: 39
The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective
Eden David, Benjamin Ungar, Yael Renert‐Yuval, et al.
Clinical & Experimental Allergy (2023) Vol. 53, Iss. 2, pp. 156-172
Closed Access | Times Cited: 29
Challenges and Future Trends in Atopic Dermatitis
Julius Garcia Gatmaitan, Ji Hyun Lee
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11380-11380
Open Access | Times Cited: 28
The use of biologics for immune modulation in allergic disease
Willem van de Veen, Mübeccel Akdiş
Journal of Clinical Investigation (2019) Vol. 129, Iss. 4, pp. 1452-1462
Open Access | Times Cited: 58
Advances in our understanding of canine atopic dermatitis
Rosanna Marsella
Veterinary Dermatology (2021) Vol. 32, Iss. 6, pp. 547-547
Open Access | Times Cited: 52
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study
Jonathan I. Silverberg, Andreas Pinter, Afsáneh Alavi, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 7, pp. 1562-1568
Closed Access | Times Cited: 44
Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study
Atsuyuki Igarashi, Toshio Katsunuma, Takayo Matsumura, et al.
British Journal of Dermatology (2023) Vol. 190, Iss. 1, pp. 20-28
Open Access | Times Cited: 16
Mast cell–sensory neuron crosstalk in allergic diseases
Chunjing Bao, Soman N. Abraham
Journal of Allergy and Clinical Immunology (2024) Vol. 153, Iss. 4, pp. 939-953
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top